Canada markets closed

Evotec SE (EVT.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
8.65-0.06 (-0.69%)
At close: 09:50PM CEST

Evotec SE

Essener Bogen 7
Hamburg 22419
49 40 560 81 0

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees5,055

Key Executives

NameTitlePayExercisedYear Born
Ms. Laetitia RouxelCFO & Member of Management Board890kN/A1975
Dr. Cord Dohrmann Ph.D.Chief Scientific Officer & Member of Management Board582kN/A1964
Dr. Matthias Evers Ph.D.Chief Business Officer & Member of Management Board130kN/A1973
Dr. Christian WojczewskiChief Executive OfficerN/AN/A1972
Dr. Craig Johnstone Ph.D.COO & Member of Management Board712kN/A1970
Ms. Aurelie DalbiezChief People Officer & Member of Management BoardN/AN/A1977
Ms. Anja BoslerPrincipal Accounting Officer and Senior Vice President of Group AccountingN/AN/AN/A
Mr. Volker BraunExecutive VP and Head of Global Investor Relations & ESGN/AN/AN/A
Dr. Christian DargelEVP Global Head of Legal & ComplianceN/AN/A1971
Gabriele HansenSenior VP & Head of Global Corporate Communications & MarketingN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Corporate Governance

Evotec SE’s ISS Governance QualityScore as of July 1, 2024 is 1. The pillar scores are Audit: 3; Board: 2; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.